Non-arteritic Anterior Ischemic Optic Neuropathy Clinical Trial
Official title:
Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study
Clinical trial.gov
Brief summary :
Non-arteritic anterior ischemic optic neuropathy (NAION) is an optic neuropathy due to acute
or subacute ischemic event of anterior optic nerve axons retrolaminar part that was
vascularized by posterior ciliary brevis artery. The incidence of ischemia will be followed
by axonal edema and causing compartment syndrome and heighten the incidence of ischemic.
In NAION, the main pathology occurs at the level of the optical nerve, the axons of retinal
ganglion cells. Initial damage is on the optic disc ischemia resulting hypoxic injury of
axons and manifest as disc edema. Axonal edema cause disturbances of retrograde axonal
transport of neurotrophic factors, especially brain derived neurotrophic factor, to the
retinal ganglion cells. This will trigger a secondary toxicity and apoptosis. In addition,
the presence of oxidative stress, calcium influx and mitochondrial damage will also triggers
apoptosis. After the apoptosis of retinal ganglion cells, there was a thinning of the retinal
nerve fiber layer (RNFL) through Wallerian degeneration. Thinning of the RNFL will manifest
as visual field defects and the decline in visual acuity in patients with chronic phase
NAION.
Though NAION include disease entity that has long existed, but until now, there has been no
evidence-based study on medical or surgical procedures that is effective enough to overcome
NAION. The main treatment is to manage the risk factor such as hypertension, dyslipidemia,
diabetes mellitus, hypercoagulable state. In general, if the patient is in the acute phase
(edema of optic nerve head), methylprednisolone administration may be considered, but if the
patient is already on chronic phase (atrophy disc) which generally occurs 6-11 weeks after
the onset, then steroids are no longer indicated. Neuroprotective agent was considered as
treatment in NAION given primary pathology NAION is the retinal ganglion cell axons. Among
the various neuroprotective substance, Citidine diphosphocoline (CDP-choline
5'-diphosphocholine or Citicoline) is a therapeutic option NAION.
Citicoline is an endogenous mononucleotide consisting of ribose, cytosine, pyrophosphate, and
choline. Citicoline is a component intermediates in the synthesis of phospholipids in cell
membranes, ie phosphatidylcholine. Exogenous citicoline administered orally or intravenously,
will be split into citidine and choline. Citicoline via oral administration can be absorbed
completely and have a similar bioavailability in the blood compared to parenteral
administration such as intravenous. Once absorbed, citicoline will be distributed throughout
the body and enter the blood-brain barrier and the blood retinal barrier penetrate into the
central nervous system. If there is damage to neurons, exogenous citicoline will participate
in the synthesis of phospholipids in the neuronal cell membrane. Some studies show that
citicoline may have a neuroprotective effect on retinal ganglion cells and supporting
regeneration of damaged neurons in vitro. Previous research on the citicoline effect in
chronic phase NAION give satisfactory results. Dopaminergic neurotransmitter systems known to
occur in vast numbers in the retina and post-retinal visual pathway. Retinal ganglion cells
using certain subtypes of dopamine as a means of communication with the visual cortex. Rejdak
et al in animal models showed that citicoline administration could improve and strengthen the
dopamine transmission in the retina. Citicoline also a safe medicine, without serious adverse
effect.
Electroretinogram (ERG) is a tool to measure the function of the retina. ERG examination can
measure electrical changes in the retina after light stimulus. ERG examination that can
detect changes in the activity of retinal ganglion cell is a pattern ERG. Spectral-domain
optical coherence tomography is a tool that can measure the thickness of retinal ganglion
cells.
Thinning of the RNFL will manifest as visual field defects in patients with NAION. The
typical visual field defects of NAION is altitudinal defects associated with segmental edema
optic nerve head.
Based on these descriptions question arises whether the citicoline supplementation can repair
damage to the neurons of the retina, especially the retinal ganglion cells, in NAION
resulting in improved retinal function which can be judged from the improvement of the value
of the amplitude of the wave of P50 and N95 in the examination pattern ERG (PERG) when
compared with placebo ? In addition whether citicoline supplementation can increase the
thickness of retinal ganglion cells assessed using SD-OCT? Does citicoline supplementation
give the effect of improving visual field defects in patients with NAION?
Research design This study is a double blind randomized clinical trial to determine
differences in wave amplitude P50 and N95 on pattern ERG examination, visual field defects
(LP) with Humphrey HFA (Humphrey Field Analyzer) II-i 750, 24-2 threshold and ganglion cell
thickness with OCT CirrusTM between the administration of citicoline and placebo in patients
with non-arteritic anterior ischemic optic neuropathy (NAION) chronic phase. Masking applied
to patients and researchers.
Research Time and Place This research was conducted at the Eye Clinic Division of
Neuro-Ophthalmology Faculty of medicine Universitas Indonesia- RSCM (Cipto Mangunkusumo
Hospital) Kirana (single centre), Jakarta, Indonesia in November 2016-June 2017.
Population and Sample Research The target population of this study is that patients with
chronic phase NAION. Samples were selected with consecutive sampling method, ie all NAION
patients with chronic phase who came to the Faculty of medicine Universitas Indonesia-RSCM
Kirana Neuro-ophthalmology division fulfilled the inclusion criteria included in the study
and randomize by researchers. If the patient NAION was in acute phase, in the further visit
became chronic phase and met the inclusion criteria, then the patient can be a sample.
Inclusion criteria
1. Patients aged 20-65 years.
2. NAION patients who have been diagnosed clinically by a minimum of 1 consultant Division
NO with onset ≥6 weeks.
3. Best corrected visual acuity ≥ 1/60 Snellen
4. Patients have to get an explanation about the purpose of the research and all the
procedures that will be undertaken and willing to participate in the study by signing
the informed consent.
5. On bilateral NAION, examination of research done on one eye at a nearby onset of 6 weeks
Exclusion criteria
1. Haziness of refractive media, such as corneal opacities and opacities in the lens of
moderate to severe (color and turbidity of the lens, the cortex and the posterior
capsule with degrees LOCs (Lens Opacity Classification System) III> 3).
2. Abnormalities in the macula and the optic disc due to causes other than NAION.
3. Patients with a history of glaucoma.
4. Patients with intraocular inflammation such as anterior and posterior uveitis.
5. Taking antioxidant supplements or other neuroprotective agents in the last 2 weeks
before randomization.
6. Edema of optic nerve head condition detected clinically or by OCT. Dropout Criteria
1. Patients which in the study drug administration period experienced NAION in the
contralateral eye so requiring steroid therapy.
2. Patients who experience severe side effects (headache, nausea, vomiting) that can not be
resolved with symptomatic medication.
Sample calculation The sample size was calculated based on previous studies that measure the
amplitude of the wave N95 PERG in patients with NAION. From previous studies we obtained a
standard deviation of 55% . The researchers set the value of minimal clinical differences
were considered significant at 0.55.
The sample size in this study was calculated based on the formula of the samples to test
numerical analytic unpaired. Sample size was 16 people per group. Taking into account the
drop out rate of 20%, is set to take a sample of 20 people for each treatment group (Group A:
citicoline and group B : placebo) Subject allocation Subjects who have fulfilled the
inclusion and exclusion criteria for the study were asked to sign an informed consent and
will randomization. The allocation of the subject is done by using block randomization.
Randomization will be performed by a third party before the study began. Number randomization
results will be incorporated into the white envelope sealed and classified into group A (got
citicoline) or group B (placebo) in accordance with the results of randomization.
Examination and Intervention
1. History taking, to obtain basic data about the patient's identity, course of the disease
at this time, a history of previous disease (systemic and ocular), and history of
previous treatment.
2. Ophthalmological examination performed include:
1. Examination of visual acuity using the Snellen chart for patients who can read or
using Illiterate E chart for patients who can not read. Examination of visual
acuity will be conducted refractionist of Department of Ophthalmology Faculty of
medicine Universitas Indonesia-RSCM Kirana.
2. Complete ophthalmological examination using a slit lamp will be conducted by the
residence of Division of Neuro-ophthalmology.
3. Examination of eye pressure using a non-contact tonometry (NCT).
4. Fundus examination by fundus photograph operator.
3. Patients who met the inclusion criteria for the study offered to follow this study.
Researchers explain the purpose and procedures of the study, how the use of a given
drug, and possible side effects of the drugs given. Patients who are willing to follow
the study were asked to sign an informed consent.
4. Subjects will be randomized into groups A (citicoline) or group B (placebo).
5. Examination of the visual field using Humphrey HFA II-i 750, 24-2 threshold by anterior
operator who has been certified.
6. Examination of retinal ganglion cell thickness using OCT Cirrus TM (Trade Mark) by
posterior operator who has been certified.
7. Examination of pattern ERG by investigators, accompanied by an expert consultant in the
Eye Clinic Division of Neuro-ophthalmology follow the standards of the International
Society for Clinical electrophysiology of Vision (ISCEV)
1. Before the examination, the eye drops of local anesthetic eye drops (pantocaine®)
and eyelid and forehead area will be cleaned by abrasive paste and given a
conductive paste.
2. Fiber electrodes placed on the top edge of the eyelid inferior border of the nasal
canthus area, reference electrodes on the skin area in the ipsilateral lateral
canthus eyelids and grounding electrodes on the forehead.
3. Standard stimulus parameter is set to be the size of a box of 0.80, luminance of 80
cd / m2, contrast 100% reversal rate of 4 rev / s.
4. Patients were asked to put the head on the head rest and a fixation on the letter X
in the middle of the screen and it is recommended not much flash.
5. Examination started and completed within 3-4 minutes to obtain a minimum of 100
free wave artifacts.
6. After completion of the examination, the patient's eye drops of antibiotic eye
drops (C. Polygran®).
8. Intervention: Subjects in group A get citicoline 1000 mg per day for 60 days while
subjects in group B get placebo for 60 days (the citicoline and placebo will be
repackage by the pharmacist).
9. During the study, subjects continue taking systemic drug such as anti-hypertensive,
anti-dyslipidemia, anti-diabetes, anti-coagulants as usual (control of risk factors) and
not taking any other multivitamins.
10. To ensure that patients taking the drug regularly study, the researchers will provide
medication logbook and asking the patient to provide a check mark after taking the drug
every day. Patients were asked to consume the drug in the morning after breakfast and a
minimum of 60 minutes of consumption of other drugs (if any). Researchers also will call
patients once a week to ensure that patients taking the study drug on a regular basis.
11. Patients will be required to control after 30 days of drug usage for examination visual
acuity, complete ophthalmologic examination, with Humphrey visual field examination,
PERG examination and thickness of retinal ganglion cells by SD-OCT. Evaluation of
logbook and noted complaints related to the side effects due to the intervention will
also be assessed during follow up.
12. After 60 days of intervention, re-examination include: visual acuity, complete
ophthalmologic examination, Humphrey visual field examination, PERG examination and
thickness of retinal ganglion cells using SD-OCT and also noted complaints related to
side effects as a result of the intervention will be assessed during final follow up.
13. The interpretation of the results of PERG performed by two expert consultants
Neuro-Ophthalmology Division (MS and SN).
Reporting Drug's Side Effects From previous studies, no serious side effects have been
reported due to the use of this drug. In case of unwanted side effects such as headaches and
gastrointestinal intolerance, researchers will ask the patient to come to the clinic Faculty
of medicine Universitas Indonesia-RSCM Kirana and will be given further handling according
the patient's condition and the researcher will decide whether the patient is still able to
continue his research. The cost of treatment side effects will be borne by the researcher.
Researchers also will ask the patient fill out a form and side effects of drugs.
Operational definition
1. Diagnosis of NAION established based on the following criteria: sudden decrease in
visual acuity, optic disc edema or atrophy of optic nerve head on funduscopy, found
relative afferent pupillary defect (if unilateral), visual field abnormalities (LP) is
consistent with NAION. The diagnosis of NAION have been confirmed by the ophtalomologist
in charge in Neuro-ophthalmology Policlinic Faculty of medicine Universitas
Indonesia-RSCM Kirana. The acute phase is onset <6 weeks and found to have edema of
optic nerve head in fundoscopy and or thickening of the Retinal Nerve Fiber Layer (RNFL)
on the basis of at least one quadrant of optic nerve head OCT. Chronic phase is ≥ 6
weeks from onset and found atrophy or normal of optic nerve head in funduscopy and RNFL
thinning on the basis of at least one quadrant of optic nerve head OCT.
2. Age: calculated based on years of research and a reduction in birth year of research
subjects.
3. Onset: calculated based on the first time the patient signed a consent form to
participate study time minus the typical complaints NAION started happening.
4. Best corrected visual acuity: the results of visual acuity using the Snellen maximum
refraction correction chart. Visual acuity with correction is then converted to logMar
5. Diabetes Mellitus (DM): The laboratory results of blood fasting blood sugar ≥ 126 mg /
dL or random blood glucose and 2-hour post-prandial ≥ 200 mg / dL with classical symptom
and or HbA1c ≥ 6.5% and or controlled DM with hypoglycemic drugs.
6. Hypertension: Results of measurement of blood pressure ≥ 140/90 mmHg and or people with
hypertension controlled with antihypertensive medication.
7. Dyslipidemia: Results of laboratory blood total cholesterol ≥ 200 mg / dL or LDL ≥ 100
mg / dL and HDL ≤ 50 mg / dL or triglyceride levels ≥ 100 mg / dL or persons with
dyslipidemia and controlled dyslipidemia drugs.
8. Hypercoagulability: blood lab results Ivy bleeding time <6 minutes or prothrombin time>
11.2 seconds and or the activated partial thromboplastin time> 47 seconds or fibrinogen
levels> 384 mg / dL or quantitative D-dimer> 300 g / dL or 1 μM platelet aggregation>
15% and 5 μM or platelet aggregation> 68% or 10 μM platelet aggregation> 84%.
9. Visual field is a visual field test results using Humphrey HFA II-i 750, 24-2 threshold.
Examination is repeated by taking into account the confidence index that meets the three
criteria below:
1. Fixation losses ≤ 20%
2. False positive ≤ 15%
3. False negative ≤ 20-30%
The parameters assessed are:
1. The mean deviation (MD): the result of the average sensitivity of the retina of
patients compared with the normal population. This figure is obtained from the
total deviation.
2. Pattern standard deviation (PSD): the result of the average sensitivity of the
retina of patients who have adapted and showed a localized area index. This figure
is obtained from the pattern deviation.
10. The thickness of the retinal ganglion cells are anatomical cross-sectional examination
of retinal ganglion cells using optical coherence tomography (OCT) Cirrus TM HD (High
Definition) -OCT 5000. The mode is panomap ganglion cell analysis: Macular Cube 512x128
and 200x200 cube Optic disc. Examination is repeated with minimal attention to signal
strength is ≥ 5.
11. PERG examination:
1. P50 wave amplitude is amplitude measured from the valley of N35 to the peak of P50.
The unit used is μV.
2. N95 wave amplitude is the amplitude measured from peak of P50 to valley of N95. The
unit used is μV.
3. P50 wave implicit time is the time measured from the light stimulus to the crest of
a wave P50. The unit used is ms.
4. N95 wave implicit time is the time measured from the light stimulus to the crest of
a wave N95. The unit used is ms.
5. Latency is the time until the occurrence of a wave response.
12. Side effects: systemic and ocular complaints at least 2 hours after study drug
consumption. Side effects that have been reported previously were headache and
gastrointestinal intolerance.
Research Ethics Once the proposal is approved by research supervisor and research coordinator
and Head of the Department of Ophthalmology Faculty of medicine Universitas Indonesia-RSCM
Kirana, then the proposal will be submitted to the Health Research Ethics Committee of the
Faculty of medicine Universitas Indonesia-RSCM for review. The study will begin after the
study passed the test of ethics and obtained a number of research protocols to meet the
Declaration of Helsinki and will be registered on the ClinicalTrials.gov website.
Data analysis Data from the study will be recorded and incorporated into the primary table,
then be processed with SPSS (Statistical Package for the Social Science) version 17.0. The
analysis is intention to treat. If there is a violation of protocols such as the incidence of
severe side-effects that provide interventions should be stopped or are lost to follow-up at
least once a second measurement is done (after 30 days), the subject will be considered a
failure but still included in the analysis. Patients were also said to drop out when during
the administration of the intervention patients had symptoms of NAION in the contralateral
eye and require steroid therapy but still included in the analysis had been carried out when
at least a second measurement is done (after 30 days). Data will be presented in the form of
tables and graphs. Data will be tested whether the distribution is spread evenly with
normality test. Data were analyzed to compare the two averages in pairs using unpaired t-test
or Mann Whitney test. Categorical data are presented in the form of proportions. Statistical
test for difference in proportions between the two independent groups using chi-square test.
Statistical tests to determine the correlation using Pearson or Spearman test.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01064505 -
Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients
|
Phase 1 | |
| Recruiting |
NCT00813059 -
Intravitreal Bevacizumab for Non-Arteritic Anterior Ischemic Optic Neuropathy
|
Phase 2 | |
| Completed |
NCT00140491 -
Vision Restoration Therapy (VRT) to Treat Non-Arteritic Anterior Ischemic Optic Neuropathy
|
N/A |